Experimental cell therapy aims to prevent relapse in aggressive childhood blood cancers
NCT ID NCT07476027
Summary
This early-phase study is testing whether a personalized cell therapy called CD7 CAR-T can help prevent cancer from returning in children and teenagers with high-risk T-cell leukemia or lymphoma. Participants must have already achieved remission with initial chemotherapy. Doctors will collect the patient's own immune cells, modify them in a lab to better target cancer, and then infuse them back into the patient to see if this approach is safe and effective at keeping the cancer away.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.